Tempus Beats Estimates with Strong Oncology Diagnostics Growth

Tempus reported strong Q1 2026 profits, exceeding analyst estimates, driven by oncology diagnostics and AI services. Despite a widened net loss, the firm raised full-year revenue guidance and announced key partnerships with Merck and Gilead.

Financial Performance Highlights

The Chicago-based accuracy medication firm published quarterly profits of $348.1 million, up from $255.7 million a year previously. The total covered analyst estimates of $345.5 million. Changed loss was available in at 13 cents per share, defeating estimates for a loss of 19 cents per share.

Tempus reported a net loss of $125.9 million, or 70 cents per share, compared to a loss of $68 million, or 40 cents per share, in the prior-year quarter. Readjusted EBITDA loss enhanced to $2.8 million from a loss of $16.2 million a year previously.

Revenue and EBITDA Outlook

Tempus increased its full-year 2026 revenue guidance to a series of $1.59 billion to $1.60 billion from prior support of $1.59 billion. The upgraded overview compares to expert price quotes of $1.592 billion. The firm maintained assumptions for adjusted EBITDA of about $65 million.

Growth Drivers and Segments

Throughout the earnings phone call, Lefkofsky said oncology diagnostics remained the main development chauffeur, with solid lump and liquid biopsy screening executing highly and very little recurring illness examination quantities climbing concerning 500% year over year to approximately 6,500 examinations.

The firm reported first-quarter 2026 profits growth of 36.1% on solid need for its oncology diagnostics and AI-driven information service, while the business widened its net loss and elevated its full-year income overview.

Hereditary testing softened as anticipated due to harder year-over-year contrasts, Lefkofsky said, though the firm expects growth in the segment to rebound to the mid-teens range in the 2nd fifty percent of the year.

Strategic Partnerships and AI

The business likewise highlighted momentum in its information licensing and AI modeling company, consisting of new calculated cooperations with Merck & Firm, Inc. (NYSE: MRK) and increased deal with Gilead Sciences, Inc.(NASDAQ: GILD). Tempus stated the Merck contract focuses on biomarker exploration and development making use of Tempus’ multimodal data and Lens logical system.

Chief executive officer Lefkofsky said the company’s new partnership with Merck places amongst its biggest critical data and AI modeling partnerships, alongside existing manage significant pharmaceutical firms including AstraZeneca PLC(NASDAQ: AZN), GSK plc(NYSE: GSK) and Bristol Myers Squibb(NYSE: BMY). He said the agreements are designed to develop long-term “sticky” partnerships with wide information gain access to, devoted teams and AI design growth.